Management of Metastatic Melanoma with New Immunotherapy Approaches beyond PD-1/CTLA-4 Inhibitors

Scientists focus on new immunotherapeutic approaches studied in advanced melanoma previously treated by anti-programmed cell death 1 (PD-1) receptor or anti-cytolytic T-lymphocyte-associated protein 4 (CTLA-4) antibodies.